Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 52
Selected: 0
NCT IDTitle
NCT04354727A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
NCT04942067APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04568265A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
NCT03537482APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
NCT06104566Global Trial in APG2575 for Patients With CLL/SLL
NCT05147467Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT03585322APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
NCT05594758Named Patient Program for Olverembatinib (HQP1351)
NCT03386526APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
NCT06182969A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
NCT05186012APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03611868A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03882281Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
NCT04501120Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT05517616The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects
NCT06389292A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia
NCT04260022Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT03594422A Study of HQP1351 in Patients With GIST or Other Solid Tumors
NCT04964518A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
NCT05773586A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
NCT03917043APG-2449 in Patients With Advanced Solid Tumors
NCT06641414Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT04126681A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT04260217APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
NCT03913949A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
NCT04674514APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04496349A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
NCT05701306APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
NCT04494503Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
NCT06401603A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
NCT04946864A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT04893759A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
NCT03883100A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
NCT03387332APG-1252 in Patients With SCLC or Advanced Solid Tumors
NCT02935907APG-115 in Patients With Advanced Solid Tumors or Lymphomas
NCT06051409A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.
NCT04126707The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
NCT04284488Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
NCT04210037Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
NCT06423911Study of Olverembatinib (HQP1351) in Patients With CP-CML
NCT04358393A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
NCT03080311A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
NCT06640361A Study of Olverembatinib in SDH-deficient GIST.
NCT04643405APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
NCT05415098Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
NCT03883087A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
NCT03781986APG-115 in Salivary Gland Cancer Trial
NCT04215809Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL